Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), a combination of at least two solubilizing and suspending agents (of which one is a non-ionic polyoxyethlene-polyoxypropylene block copolymer), and a carrier. Methods for fabricating the compositions and using them are also described.
1. A method for treating an ophthalmological disease, condition or pathology in a mammalian subject in need of such treatment comprising delivering to the subject by intraocular injection, an effective amount of a composition comprising:
(a) a therapeutically effective quantity of triamcinolone or a derivative thereof;
(b) a therapeutically effective quantity of moxifloxacin;
(c) a non-ionic poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) block copolymer having a molecular weight of the polyoxypropylene portion of about 4,000 Daltons and about a 70% polyoxyethylene content, with an overall molecular weight of between about 9,840 Daltons and about 14,600 Daltons, wherein the concentration of the non-ionic polyoxyethlene-polyoxypropylene block copolymer is between about 1 mass % and about 2 mass % of the pharmaceutical composition;
(d) about 1% of polysorbate 80; and
(e) a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein said composition further comprises a therapeutically effective quantity of a glycopeptide antibiotic selected from the group consisting of vancomycin, teicoplanin, telavancin, decaplanin, ramoplanin, gentamicin, tobramycin, amikacin, cefuroxime, polymyxin B sulfate, trimethoprim, and a combination thereof.
3. The method of claim 2 , wherein said antibiotic is vancomycin.
4. The method of claim 1 , wherein said pharmaceutically acceptable carrier is selected from the group consisting of sterile water, a sterile water solution of edetate calcium disodium, a sterile water solution of hydrochloric acid, and combinations thereof.
5. The method of claim 1 , wherein said intraocular injection comprises intravitreal injection.
6. The method of claim 1 , wherein said intraocular injection comprises intracameral injection.
7. The method of claim 5 , wherein the intravitreal injection is intraoperative.